Serum amyloid A is an endogenous ligand that differentially induces IL-12 and IL-23

Journal of Immunology

Volumn 177, Issue 6, 2006, Pages 4072-4079

  He, Rong ^a   Shepard, Larry W ^a   Chen, Jia ^a   Pan, Zhixing K ^b   Ye, Richard D ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CCAAT ENHANCER BINDING PROTEIN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 23P19; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; POLYMYXIN B; SERUM AMYLOID A; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNITY; INFECTION; INFLAMMATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; TH1 CELL;

EID: 33748499140     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.6.4072     Document Type: Article

References (64)

1. Gabay, C., and I. Kushner. 1999. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340: 448-454.
2. Baumann, H., and J. Gauldie. 1994. The acute phase response. Immunol. Today 15: 74-80.
3. Uhlar, C. M., and A. S. Whitehead. 1999. Serum amyloid A, the major vertebrate acute-phase reactant. Eur. J. Biochem. 265: 501-523.
4. Urieli-Shoval, S., R. P. Linke, and Y. Matzner. 2000. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr. Opin. Hematol. 7: 64-69.
5. Malle, E., and F. C. De Beer. 1996. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur. J. Clin. Invest. 26: 427-435.
6. Fyfe, A. I., L. S. Rothenberg, F. C. DeBeer, R. M. Cantor, J. I. Rotter, and A. J. Lusis. 1997. Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation 96: 2914-2919.
7. Chambers, R. E., D. G. MacFarlane, J. T. Whicher, and P. A. Dieppe. 1983. Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann. Rheum. Dis. 42: 665-667.
8. Chambers, R. E., P. Stross, R. E. Barry, and J. T. Whicher. 1987. Serum amyloid A protein compared with C-reactive protein, α1-antichymotrypsin and α1-acid glycoprotein as a monitor of inflammatory bowel disease. Eur. J. Clin. Invest. 17: 460-467.
9. Liuzzo, G., L. M. Biasucci, A. G. Rebuzzi, J. R. Gallimore, G. Caligiuri, G. A. Lanza, G. Quaranta, C. Monaco, M. B. Pepys, and A. Maseri. 1996. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation 94: 2373-2380.
10. Willerson, J. T., and P. M. Ridker. 2004. Inflammation as a cardiovascular risk factor. Circulation 109: 112-10.
11. Black, S., I. Kushner, and D. Samols. 2004. C-reactive protein. J. Biol. Chem. 279: 48487-48490.
12. Yeh, E. T. 2004. CRP as a mediator of disease. Circulation 109: II11-14.
13. Jensen, L. E., and A. S. Whitehead. 1998. Regulation of serum amyloid A protein expression during the acute-phase response. Biochem. J. 334: 489-503.
14. Benditt, E. P., and N. Eriksen. 1977. Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc. Natl. Acad. Sci. USA 74: 4025-4028.
15. Banka, C. L., T. Yuan, M. C. de Beer, M. Kindy, L. K. Curtiss, and F. C. de Beer. 1995. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J. Lipid Res. 36: 1058-1065.
16. Hosoai, H., N. R. Webb, J. M. Glick, U. J. Tietge, M. S. Purdom, F. C. de Beer, and D. J. Rader. 1999. Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. J. Lipid Res. 40: 648-653.
17. Meek, R. L., S. Urieli-Shoval, and E. P. Benditt. 1994. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc. Natl. Acad. Sci. USA 91: 3186-3190.
18. Kumon, Y., T. Suehiro, K. Hashimoto, K. Nakatani, and J. D. Sipe. 1999. Local expression of acute phase serum amyloid A mRNA in rheumatoid arthritis synovial tissue and cells. J. Rheumatol. 26: 785-790.
19. Cunnane, G. 2001. Amyloid precursors and amyloidosis in inflammatory arthritis. Curr. Opin. Rheumatol. 13: 67-73.
20. Su, S. B., W. Gong, J. L. Gao, W. Shen, P. M. Murphy, J. J. Oppenheim, and J. M. Wang. 1999. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J. Exp. Med. 189: 395-402.
21. Yan, S. D., H. Zhu, A. Zhu, A. Golabek, H. Du, A. Roher, J. Yu, C. Soto, A. M. Schmidt, D. Stern, and M. Kindy. 2000. Receptor-dependent cell stress and amyloid Accumulation in systemic amyloidosis. Nat. Med. 6: 643-651.
22. Cai, L., M. C. de Beer, F. C. de Beer, and D. R. van der Westhuyzen. 2005. Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J. Biol. Chem. 280: 2954-2961.
23. + T-lymphocytes. FEBS Lett. 472: 259-262.
24. Urieli-Shoval, S., G. Shubinsky, R. P. Linke, M. Fridkin, I. Tabi, and Y. Matzner. 2002. Adhesion of human platelets to serum amyloid A. Blood 99: 1224-1229.
25. Walder, K., L. Kantham, J. S. McMillan, J. Trevaskis, L. Kerr, A. De Silva, T. Sunderland, N. Godde, Y. Gao, N. Bishara, et al. 2002. Tanis: a link between type 2 diabetes and inflammation? Diabetes 51: 1859-1866.
26. + T cells. J. Immunol. 156: 1189-1195.
27. Fearon, D. T., and R. M. Locksley. 1996. The instructive role of innate immunity in the acquired immune response. Science 272: 50-53.
28. He, R., H. Sang, and R. D. Ye. 2003. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 101: 1572-1581.
29. Furlaneto, C. J., and A. Campa. 2000. A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-1β, interleukin-1β, and interleukin-8 by human blood neutrophil. Biochem. Biophys. Res. Commun. 268: 405-408.
30. Vallon, R., F. Freuler, N. Desta-Tsedu, A. Robeva, J. Dawson, P. Wenner, P. Engelhardt, L. Boes, J. Schnyder, C. Tschopp, et al. 2001. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J. Immunol. 166: 2801-2807.
31. Patel, H., R. Fellowes, S. Coade, and P. Woo. 1998. Human serum amyloid A has cytokine-like properties. Scand. J. Immunol. 48: 410-418.
32. Langrish, C. L., B. S. McKenzie, N. J. Wilson, R. de Waal Malefytqq, R. A. Kastelein, and D. J. Cua. 2004. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 202: 96-105.
33. Murphy, T. L., M. G. Cleveland, P. Kulesza, J. Magram, and K. M. Murphy. 1995. Regulation of interleukin 12 p40 expression through an NF-κB half-site. Mol. Cell. Biol. 15: 5258-5267.
34. Hara, K., K. Yonezawa, H. Sakaue, A. Ando, K. Kotani, T. Kitamura, Y. Kitamura, H. Ueda, L. Stephens, T. R. Jackson, et al. 1994. 1- Phosphatidylinositol 3-kinase activity is required for insulin-stimulated glucose transport but not for RAS activation in CHO cells. Proc. Natl. Acad. Sci. USA 91: 7415-7419.
35. Gingras, A. C., S. G. Kennedy, M. A. O'Leary, N. Sonenberg, and N. Hay. 1998. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 12: 502-513.
36. Huang, S., Y. Jiang, Z. Li, E. Nishida, P. Mathias, S. Lin, R. J. Ulevitch, G. R. Nemerow, and J. Han. 1997. Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. Immunity 6: 739-749.
37. Dignam, J, D., R. M. Lebovitz, and R. G. Roeder. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11: 1475-1489.
38. Kravchenko, V. V., Z. Pan, J. Han, J. M. Herbert, R. J. Ulevitch, and R. D. Ye. 1995. Platelet-activating factor induces NF-κB activation through a G protein-coupled pathway. J. Biol. Chem. 25: 14928-14934.
39. Ma, X., and G. Trinchieri. 2001. Regulation of interleukin-12 production in antigen-presenting cells. Adv. Immunol. 79: 55-92.
40. Stokes, D. C., J. L. Shenep, M. Fishman, W. K. Hildner, G. K. Bysani, and K. Rufus. 1989. Polymyxin B prevents lipopolysaccharide-induced release of tumor necrosis factor-α from alveolar macrophages. J. Infect. Dis. 160: 52-57.
41. Rifkind, D. 1967. Prevention by polymyxin B of endotoxin lethality in mice. J. Bacteriol 93: 1463-1464.
42. Plevy, S. E., J. H. Gemberling, S. Hsu, A. J. Dorner, and S. T. Smale. 1997. Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Rel proteins. Mol. Cell. Biol. 17: 4572-4588.
43. D'Andrea, A., M. Rengaraju, N. M. Valiante, J. Chehimi, M. Kubin, M. Aste, S. H. Chan, M. Kobayashi, D. Young, E. Nickbarg, et al. 1992. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J. Exp. Med. 176: 1387-1398.
44. Jijon, H. B., K. L. Madsen, J. W. Walker, B. Allard, and C. Jobin. 2005. Serum amyloid A activates NF-κB and proinflammatory gene expression in human and murine intestinal epithelial cells. Eur. J. Immunol. 35: 718-726.
45. Baranova, I. N., T. G. Vishnyakova, A. V. Bocharov, R. Kurlander, Z. Chen, M. L. Kimelman, A. T. Remaley, G. Csako, F. Thomas, T. L. Eggerman, and A. P. Patterson. 2005. Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J. Biol. Chem. 280: 8031-8040.
46. Lee, H. Y., M. K. Kim, K. S. Park, Y. H. Bae, J. Yun, J. I. Park, J. Y. Kwak, and Y. S. Bae. 2005. Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem. Biophys. Res. Commun. 330: 989-998.
47. Zhang, J. S., W. G. Feng, C. L. Li, X. Y. Wang, and Z. L. Chang. 2000. NF-κB regulates the LPS-induced expression of interleukin 12 p40 in murine peritoneal macrophages: roles of PKC, PKA, ERK, p38 MAPK, and proteasome. Cell. Immunol. 204: 38-45.
48. Goodridge, H. S., W. Harnett, F. Y. Liew, and M. M. Harnett. 2003. Differential regulation of interleukin-12 p40 and p35 induction via Erk mitogen-activated protein kinase-dependent and -independent mechanisms and the implications for bioactive IL-12 and IL-23 responses. Immunology 109: 415-425.
49. Fukao, T., and S. Koyasu. 2003. PI3K and negative regulation of TLR signaling. Trends Immunol. 24: 358-363.
50. Fukao, T., M. Tanabe, Y. Terauchi, T. Ota, S. Matsuda, T. Asano, T. Kadowaki, T. Takeuchi, and S. Koyasu. 2002. PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat. Immunol. 3: 875-881.
51. Martin, M., R. E. Schifferle, N. Cuesta, S. N. Vogel, J. Katz, and S. M. Michalek. 2003. Role of the phosphatidylinositol 3 kinase-Akt pathway in the regulation of IL-10 and IL-12 by Porphyromonas gingivalis lipopolysaccharide. J. Immunol. 171: 717-725.
52. Williams, D. L., C. Li, T. Ha, T. Ozment-Skelton, J. H. Kalbfleisch, J. Preiszner, L. Brooks, K. Breuel, and J. B. Schweitzer. 2004. Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis. J. Immunol. 172: 449-456.
53. Waggoner, S. N., M. W. Cruise, R. Kassel, and Y. S. Hahn. 2005. gClq receptor ligation selectively down-regulates human IL-12 production through activation of the phosphoinositide 3-kinase pathway. J. Immunol. 175: 4706-4714.
54. Liu, I., S. Cao, L. M. Herman, and X. Ma. 2003. Differential regulation of interleukin (IL)-12 p35 and p40 gene expression and interferon (IFN)-γ-primed IL-12 production by IFN regulatory factor 1. J. Exp. Med. 198: 1265-1276.
55. Goriely, S., C. Van Lint, R. Dadkhah, M. Libin, D. De Wit, D. Demonte, F. Willems, and M. Goldman. 2004. A defect in nucleosome remodeling prevents IL-12(p35) gene transcription in neonatal dendritic cells. J. Exp. Med. 199: 1011-1016.
56. 2 is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 97: 3466-3469.
57. Chan, S. H., B. Perussia, J. W. Gupta. M. Kobayashi, M. Pospisil, H. A. Young, S. F. Wolf, D. Young, S. C. Clark, and G. Trinchieri. 1991. Induction of interferon γ production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J. Exp. Med. 173: 869-879.
58. Langrish, C. L., Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham, J. D. Sedgwick, T. McClanahan, R. A. Kastelein, and D. J. Cua. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201: 233-240.
59. Aggarwal, S., N. Ghilardi, M. H. Xie, F. J. de Sauvage, and A. L. Gurney. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278: 1910-1914.
60. Murphy, C. A., C. L. Langrish, Y. Chen, W. Blumenschein, T. McClanahan, R. A. Kastelein, J. D. Sedgwick, and D. J. Cua. 2003. Divergent pro-and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198: 1951-1957.
61. Cua, D. J., J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
62. Fossiez, F., O. Djossou, P. Chomarat, L. Flores-Romo, S. Ait-Yahia, C. Maat, J. J. Pin, P. Garrone, E. Garcia, S. Saeland, et al. 1996. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183: 2593-2603.
63. Stark, M. A., Y. Huo, T. L. Burcin, M. A. Morris, T. S. Olson, and K. Ley. 2005. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 22: 285-294.
64. Zhang, N., M. H. Ahsan, A. F. Purchio, and D. B. West. 2005. Serum amyloid A-luciferase transgenic mice: response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition. J. Immunol. 174: 8125-8134.